SG183069A1 - Treatment of post-traumatic stress disorder - Google Patents

Treatment of post-traumatic stress disorder Download PDF

Info

Publication number
SG183069A1
SG183069A1 SG2012054540A SG2012054540A SG183069A1 SG 183069 A1 SG183069 A1 SG 183069A1 SG 2012054540 A SG2012054540 A SG 2012054540A SG 2012054540 A SG2012054540 A SG 2012054540A SG 183069 A1 SG183069 A1 SG 183069A1
Authority
SG
Singapore
Prior art keywords
nepicastat
post
patient
dopamine
compound
Prior art date
Application number
SG2012054540A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics filed Critical Synosia Therapeutics
Publication of SG183069A1 publication Critical patent/SG183069A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG2012054540A 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder SG183069A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23

Publications (1)

Publication Number Publication Date
SG183069A1 true SG183069A1 (en) 2012-08-30

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012054540A SG183069A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Country Status (12)

Country Link
US (1) US20090054403A1 (enExample)
EP (1) EP2182952A4 (enExample)
JP (1) JP2010534676A (enExample)
CN (1) CN101951912A (enExample)
AU (1) AU2008279091A1 (enExample)
CA (1) CA2707858A1 (enExample)
CO (1) CO6260078A2 (enExample)
MX (1) MX2010000937A (enExample)
NZ (1) NZ583193A (enExample)
RU (1) RU2458691C2 (enExample)
SG (1) SG183069A1 (enExample)
WO (1) WO2009015248A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015236A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
MX391921B (es) * 2007-08-06 2025-03-21 Biotie Therapies Inc Nepicastat para usarse en el tratamiento de dependencia
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HRP20200055T1 (hr) 2013-03-15 2020-04-03 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin-klorovodika i manitola
JP6364488B2 (ja) * 2013-11-26 2018-07-25 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ 認知欠損を治療するための個別化医療的手法
JP6614724B2 (ja) 2014-09-18 2019-12-04 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
US10588890B2 (en) * 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
US11284934B2 (en) * 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
EP3720856A1 (en) 2017-12-04 2020-10-14 BIAL - PORTELA & Cª, S.A. Dopamine-& x392;-hydroxylase inhibitors
JP2021505629A (ja) 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
US20220313647A1 (en) * 2019-07-25 2022-10-06 Tokyo University Of Science Foundation Agent for treating, preventing or improving psychiatric and nervous system disorders or symptoms
KR20250116086A (ko) * 2022-11-30 2025-07-31 블링크랩 리미티드 안검 추적을 이용한 정신약리학적 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US20050209218A1 (en) * 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
EP1898915A4 (en) * 2005-07-06 2009-01-21 Sepracor Inc COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Also Published As

Publication number Publication date
US20090054403A1 (en) 2009-02-26
CO6260078A2 (es) 2011-03-22
NZ583193A (en) 2012-05-25
RU2458691C2 (ru) 2012-08-20
WO2009015248A1 (en) 2009-01-29
CN101951912A (zh) 2011-01-19
MX2010000937A (es) 2010-06-25
JP2010534676A (ja) 2010-11-11
RU2010106014A (ru) 2011-08-27
CA2707858A1 (en) 2009-01-29
EP2182952A1 (en) 2010-05-12
EP2182952A4 (en) 2010-09-08
AU2008279091A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
SG183069A1 (en) Treatment of post-traumatic stress disorder
US20200383951A1 (en) Methods for treating dependence
US20140142140A1 (en) Pharmaceutical composition for neurological disorders
AU2018203524B2 (en) Methods for treating dependence
Chiou et al. 9-hydroxycanthin-6-one induces penile erection and delays ejaculation
AU2020326244B2 (en) Compound for combination treatment
US20220062265A1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
Escher et al. Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice
AU2014202047A1 (en) Methods for treating dependence
HK1155063A (en) Treatment of post-traumatic stress disorder
US12263155B2 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
HK1241721A1 (en) Methods for treating dependence
HK1143038A (en) Methods for treating dependence
STEINHEYER et al. Basic and Clinical Aspects of Depression
JP2009057303A (ja) 中枢性排尿障害の治療剤